Ariel Hurley Sells 1,819 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 1,819 shares of Blueprint Medicines stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $93.26, for a total transaction of $169,639.94. Following the sale, the insider now owns 14,967 shares in the company, valued at approximately $1,395,822.42. This trade represents a 10.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Blueprint Medicines Price Performance

BPMC opened at $96.48 on Wednesday. The company has a fifty day moving average price of $92.33 and a two-hundred day moving average price of $97.32. The firm has a market capitalization of $6.13 billion, a PE ratio of -45.73 and a beta of 0.59. Blueprint Medicines Co. has a 52 week low of $72.24 and a 52 week high of $121.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. During the same period in the previous year, the firm earned ($2.20) earnings per share. The firm’s quarterly revenue was up 126.5% compared to the same quarter last year. As a group, analysts anticipate that Blueprint Medicines Co. will post -3.68 earnings per share for the current year.

Institutional Trading of Blueprint Medicines

A number of hedge funds have recently modified their holdings of the company. Hsbc Holdings PLC acquired a new position in Blueprint Medicines during the second quarter valued at approximately $1,060,000. Federated Hermes Inc. grew its holdings in shares of Blueprint Medicines by 27.8% in the 2nd quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock valued at $6,721,000 after buying an additional 13,579 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Blueprint Medicines by 48.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock valued at $23,332,000 after buying an additional 82,693 shares in the last quarter. Nicholas Investment Partners LP acquired a new stake in Blueprint Medicines during the 2nd quarter worth $4,377,000. Finally, Entropy Technologies LP bought a new position in Blueprint Medicines during the third quarter worth about $999,000.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on BPMC shares. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a report on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, November 15th. UBS Group started coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They issued a “neutral” rating and a $88.00 target price for the company. Wells Fargo & Company decreased their price target on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Finally, JPMorgan Chase & Co. started coverage on Blueprint Medicines in a report on Thursday, November 14th. They set an “overweight” rating and a $126.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines currently has an average rating of “Moderate Buy” and a consensus price target of $122.11.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.